Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

Core Viewpoint - Pelthos Therapeutics Inc. has appointed Andrew J. Einhorn to its Board of Directors, effective immediately, to enhance its strategic financial guidance as it grows as a commercially focused biopharmaceutical company [1][3]. Company Overview - Pelthos Therapeutics is a biopharmaceutical company dedicated to commercializing innovative therapeutic products for unmet patient needs, with its lead product ZELSUVMI™ (berdazimer) topical gel approved by the U.S. FDA in 2024 for treating molluscum contagiosum [5]. Leadership Addition - Andrew J. Einhorn brings over four decades of experience in finance, capital markets, and life sciences, having held C-level finance roles and worked in investment banking [2][4]. - His appointment increases the Pelthos Board to eight directors, and he will also serve on the Audit Committee and Compensation Committee [1][3]. Strategic Importance - Einhorn's extensive experience in accelerating growth at public and private life science companies is expected to be critical for Pelthos as it aims to expand its commercial focus [3][4]. - The company is optimistic about its future, with Einhorn expressing excitement about collaborating with the Board to enhance Pelthos' mission [5].